The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice.


Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 26 02 2020
revised: 20 09 2020
accepted: 26 09 2020
pubmed: 6 10 2020
medline: 16 11 2021
entrez: 5 10 2020
Statut: ppublish

Résumé

Frontotemporal dementia (FTD) and Alzheimer's disease (AD) exhibit intracellular inclusions [neurofibrillary tangles (NFT's)] of microtubule-associated protein tau that contributes to neuronal dysfunction and death. Mutations in the microtubule-associated protein tau (MAPT) gene leads to tau hyperphosphorylation and promotes NFT formation. The TAU58/2 transgenic mouse model expresses mutant human tau (P301S mutation) and exhibits behavioural abnormalities relevant to dementia in early adulthood. Here we comprehensively determined the behavioural phenotype of TAU58/2 transgenic female mice at 14 months of age using test paradigms relevant to FTD and AD. TAU58/2 females showed a significant motor deficit and lower bodyweight compared to WT littermates. Transgenic females failed to habituate to the test arena in the light-dark test. Interestingly, transgenics did not exhibit an anxiolytic-like phenotype and intermediate-term spatial learning in the cheeseboard test was intact. However, a significant learning deficit was detected in the 1st trial across test days indicating impaired long-term spatial memory. In addition, the preference for a previously rewarded location was absent in transgenic females during probe trial testing. Finally, TAU58/2 mice had a defective acoustic startle response and impaired sensorimotor gating. In conclusion TAU58/2 mice exhibit several behavioural deficits that resemble those observed in human FTD and AD. Additionally, we observed a novel startle response deficit in these mice. At 14 months of age, TAU58/2 females represent a later disease stage and are therefore a potentially useful model to test efficacy of therapeutics to reverse or ameliorate behavioural deficits in post-onset tauopapthy-related neurodegenerative disorders.

Identifiants

pubmed: 33017638
pii: S0166-4328(20)30642-2
doi: 10.1016/j.bbr.2020.112943
pii:
doi:

Substances chimiques

MAPT protein, human 0
Mutant Proteins 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112943

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Fabian Kreilaus (F)

School of Medicine, Western Sydney University, NSW 2560, Australia.

Rebecca Masanetz (R)

School of Medicine, Western Sydney University, NSW 2560, Australia; Faculty of Medical and Life Sciences, Hochschule Furtwangen University, 78054 Villingen-Schwenningen, Germany.

Georgia Watt (G)

School of Medicine, Western Sydney University, NSW 2560, Australia.

Magdalena Przybyla (M)

Dementia Research Centre, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.

Arne Ittner (A)

Dementia Research Centre, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.

Lars Ittner (L)

Dementia Research Centre, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.

Tim Karl (T)

School of Medicine, Western Sydney University, NSW 2560, Australia; Neuroscience Research Australia (NeuRA), NSW 2031, Australia; School of Medical Sciences, University of New South Wales, NSW 2052, Australia. Electronic address: t.karl@westernsydney.edu.au.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH